Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas

Inclusion Criteria: * Histology: GBM, AA or grade 3 or greater WHO astrocytic, oligodendroglial or mixed glial tumors which were initially diagnosed by histologic exam of biopsy/resection * Age: \> or equal to 18 years * Performance Status: Karnofsky Performance Status \> or equal to 60% at study entry. * Renal Function: Serum creatinine \< 1.5 mg/dl or creatinine clearance \> 60 ml/dL. * Hematologic Status: The following baseline studies will be required before entry: total granulocyte count \> or equal to 1000/microliter; platelet count \> 100,000/microliter * Hepatic Function: Serum SGOT \& total bilirubin \< or equal to 2.5 times ULN. * Note: All lab parameters must have been obtained within 1 week of registration * Consent: Signed informed consent, approved by IRB, will be obtained prior to initiating treatment * Corticosteroids: For patients currently on corticosteroids, patients should be on stable dose for 1 week prior to study entry, if clinically possible. * Prior Therapy: Interval of at least 2 weeks between prior surgical resection or prior radiotherapy (XRT) or 1 week from completion of chemotherapy and all toxicities are \< or equal to grade 1 \& enrollment on this protocol unless there is unequivocal evidence of progressive disease. * Patients with Reproductive Potential: Patients must agree to practice effective birth control measures while on study and for 2 months after completing therapy Exclusion Criteria: * Pregnant or breast feeding women or women or …